PATENT CLAIM ANALYSIS

Application Number: 16138418
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "133100"]

Abstract:
Agents that specifically bind TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.

Claim (Index 247):
The method of  claim 243 , wherein the immune response is against a tumor or cancer.

Metadata:
- Claim Count in Document: 83.0
- Percentile: 97.0
- Lexical Diversity: 1.3125
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15167166', '15817691', '15449665', '14318247', '14795811']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.795417931319249
- 35 USC 102 Novelty (BERT): 0.5882184572305693
- Combined Prediction Score: 0.774697983910381
- Mean Citation Score: 489.23687000000007
- Max Citation Score: 645.2174
- Similarity Product: 389.7402890527725

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test